Mining the host-pathogen interface to deliver a drug pipeline for treating intractable and emerging infections
- Funded by National Health and Medical Research Council (NHMRC)
- Total publications:0 publications
Grant number: GA201458
Grant search
Key facts
Disease
Disease XStart & end year
20222026Known Financial Commitments (USD)
$3,605,995Funder
National Health and Medical Research Council (NHMRC)Research Location
AustraliaLead Research Institution
The University of QueenslandResearch Priority Alignment
N/A
Research Category
Therapeutics research, development and implementationResearch Subcategory
Pre-clinical studiesSpecial Interest Tags
N/AStudy Type
Non-ClinicalClinical Trial Details
N/ABroad Policy Alignment
PendingAge Group
Not ApplicableVulnerable Population
Not applicableOccupations of Interest
Not applicable
Abstract
Emerging viruses and antibiotic-resistant superbugs are the most important challenge to human health in the 21st century. New viruses such as SARS-CoV2 and Zika, as well as antibiotic resistant superbugs, emerge regularly and rapidly, urgently requiring new therapies. Our multidisciplinary Synergy team has demonstrated success in drug development and will create new drugs to avert the imminent global health disaster posed by emerging viruses and superbugs.